Key result
Higher baseline Galectin-3 levels independently predicted left ventricular remodelling at 6 months after anterior STEMI treated by primary PCI.
Why the study?
Do baseline Galectin-3 levels predict left ventricular remodelling in patients with anterior STEMI treated by primary PCI?
Cohort (n=103)
Do baseline Galectin-3 levels predict left ventricular remodelling in patients with anterior STEMI treated by primary PCI?
Galectin-3 serum levels measured during hospitalization independently predict left ventricular remodelling at 6 months in patients with anterior STEMI treated by primary PCI.
Answers are grounded in this paper and cite their sources.
Galectin-3 may aid post-STEMI remodelling risk stratification; leaves open incremental value and therapeutic implications.
OBJECTIVES: Despite modern reperfusion therapies, left ventricular remodelling (LVR) occurs frequently after an ST-elevated myocardial infarction (STEMI) and represents a strong predictor of mortality and heart failure. Galectin-3 (Gal-3), a novel biomarker involved in inflammation, tissue repair and fibrogenesis, might be a valuable predictor of LVR. METHODS: We enrolled consecutively admitted patients with a first anterior STEMI and left anterior descending artery occlusion treated by primary percutaneous coronary intervention (pPCI). Gal-3, N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography and cardiovascular events were evaluated 48 hours after admission, at 1 and 6 months. LVR was defined as a ≥15% increase in LV end-systolic volume. RESULTS: We recruited 103 patients (28% women, aged 64.6±12 years, LV ejection fraction 47±11%). Median baseline Gal-3 and NT-proBNP levels were 13.2 ng/mL (10.8-17.1 ng/mL) and 2132 pg/mL (1019-4860 pg/mL) respectively. During 6 months of follow-up, 4 patients dropped out, 7 died and 26 (28.3%) of the 92 survivors developed LVR (LVR+). LVR+ patients had higher Gal-3 levels at baseline, 1 and 6 months than LVR- (p<0.0001). By univariable logistic regression, age, female gender, higher baseline Gal-3 and NT-proBNP, smaller LV end-diastolic volume (LVEDV) were associated to an increased risk of LVR. By multivariable analysis, only LVEDV (OR 0.96, 95% CI 0.93 to 0.99/1 mL change) and Gal-3 levels (OR 1.22, 95% CI 1.06 to 1.42/1 ng/mL change) independently predicted LVR (C-statistics 0.84, 95% CI 0.75 to 0.93). CONCLUSION: Gal-3 serum levels measured during hospitalisation could be clinically useful in predicting LVR among patients admitted with anterior STEMI treated by pPCI.
No takes yet. Share an insight, caveat, or question.
Tano et al. (2016) conducted a cohort in Anterior ST-elevated myocardial infarction (STEMI) (n=103). Galectin-3 (Gal-3) levels was evaluated on Left ventricular remodelling (LVR) defined as a ≥15% increase in LV end-systolic volume (OR 1.22, 95% CI 1.06 to 1.42, p=<0.0001). Higher baseline Galectin-3 levels independently predicted left ventricular remodelling at 6 months after anterior STEMI treated by primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: